NYSE:CNMD CONMED (CNMD) Stock Price, News & Analysis $36.60 +1.11 (+3.12%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$36.60 +0.00 (+0.01%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CONMED Stock (NYSE:CNMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CONMED alerts:Sign Up Key Stats Today's Range$35.16▼$36.9250-Day Range$33.48▼$40.1152-Week Range$33.21▼$60.80Volume392,724 shsAverage Volume451,366 shsMarket Capitalization$1.10 billionP/E Ratio20.68Dividend YieldN/APrice Target$43.80Consensus RatingReduce Company Overview CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology. CONMED operates two principal segments: Orthopedics, and Visualization & Energy. The Orthopedics segment offers arthroscopic shavers, burrs and handpieces, as well as joint repair and reconstruction implants. In its Visualization & Energy segment, CONMED provides endoscopic imaging systems, electrosurgical and radiofrequency generators, insufflators, ablation devices and related disposables. These technologies are designed to improve procedural efficiency, safety and patient outcomes. With a presence in over 70 countries, CONMED sells products through direct sales forces as well as distributor partnerships. The company’s international footprint spans North America, Europe, Latin America, Asia Pacific and select emerging markets. CONMED works closely with healthcare facilities and surgical centers to deliver training, technical support and service solutions tailored to local regulatory requirements and clinical practices. Leadership at CONMED includes President and Chief Executive Officer Jeffrey M. Dunn, whose tenure has focused on strategic growth through product innovation and targeted acquisitions. Over its history, the company has expanded both organically and via the integration of complementary businesses to broaden its capabilities in key procedural areas. CONMED remains committed to advancing minimally invasive surgical technologies and supporting clinicians worldwide.AI Generated. May Contain Errors. Read More CONMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCNMD MarketRank™: CONMED scored higher than 41% of companies evaluated by MarketBeat, and ranked 551st out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingReduce Consensus RatingCONMED has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialCONMED has a consensus price target of $43.80, representing about 19.7% upside from its current price of $36.60.Amount of Analyst CoverageCONMED has only been the subject of 4 research reports in the past 90 days.Read more about CONMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth11.19% Earnings GrowthEarnings for CONMED are expected to grow by 11.19% in the coming year, from $4.38 to $4.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CONMED is 20.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.47.Price to Earnings Ratio vs. SectorThe P/E ratio of CONMED is 20.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.64.Price to Earnings Growth RatioCONMED has a PEG Ratio of 1.59. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCONMED has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CONMED's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.26% of the float of CONMED has been sold short.Short Interest Ratio / Days to CoverCONMED has a short interest ratio ("days to cover") of 5.46.Change versus previous monthShort interest in CONMED has recently increased by 7.33%, indicating that investor sentiment is decreasing significantly. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldCONMED does not currently pay a dividend.Dividend GrowthCONMED does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CONMED will have a dividend payout ratio of 12.32% next year. This indicates that CONMED will be able to sustain or increase its dividend. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for CONMED this week, compared to 3 articles on an average week.Search Interest5 people have searched for CNMD on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CONMED insiders have not sold or bought any company stock.Percentage Held by Insiders0.28% of the stock of CONMED is held by insiders.Percentage Held by InstitutionsCONMED has minimal institutional ownership at this time.Read more about CONMED's insider trading history. Receive CNMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNMD Stock News HeadlinesFinancial Survey: CONMED (NYSE:CNMD) and McKesson (NYSE:MCK)3 hours ago | americanbankingnews.comCONMED (NYSE:CNMD) Given New $40.00 Price Target at Bank of America4 hours ago | americanbankingnews.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 19 at 1:00 AM | Paradigm Press (Ad)CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of "Reduce" from BrokeragesMay 12, 2026 | americanbankingnews.comPiper Sandler Reaffirms Their Hold Rating on Conmed (CNMD)May 12, 2026 | theglobeandmail.com5 revealing analyst questions from CONMED’s Q1 earnings callMay 6, 2026 | msn.comDoes CONMED (CNMD) Refocusing Away From Gastroenterology Clarify Its Long-Term Surgical Growth Story?May 5, 2026 | finance.yahoo.comAssessing CONMED (CNMD) Valuation After A Mixed Stretch In Recent Share PerformanceMay 4, 2026 | finance.yahoo.comSee More Headlines CNMD Stock Analysis - Frequently Asked Questions How have CNMD shares performed this year? CONMED's stock was trading at $40.56 at the beginning of 2026. Since then, CNMD stock has decreased by 9.8% and is now trading at $36.5970. How were CONMED's earnings last quarter? CONMED Corporation (NYSE:CNMD) announced its quarterly earnings results on Wednesday, April, 29th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. CONMED's revenue for the quarter was down 1.3% on a year-over-year basis. Read the conference call transcript. Who are CONMED's major shareholders? Top institutional investors of CONMED include Dimensional Fund Advisors LP (4.63%), Sei Investments Co. (3.34%), Allspring Global Investments Holdings LLC (1.94%) and Arrowstreet Capital Limited Partnership (1.39%). Insiders that own company stock include Charles Farkas, Pat Beyer, Brian Concannon, Curt R Hartman, Martha Goldberg Aronson, Barbara J Schwarzentraub, John D Ferrell, Stanley W Peters III, Todd W Garner and Richard Glaze. View institutional ownership trends. How do I buy shares of CONMED? Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CONMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that CONMED investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings4/29/2026Today5/19/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (32m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CNMD's financial health is in the Red zone, according to TradeSmith. CNMD has been in this zone for over 32 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED/DENTAL - SUPP Sub-IndustryMedical Equipment Current SymbolNYSE:CNMD CIK816956 Webwww.conmed.com Phone(727) 392-6464Fax315-797-0321Employees3,900Year Founded1970Price Target and Rating Average Price Target for CONMED$43.80 High Price Target$61.00 Low Price Target$39.00 Potential Upside/Downside+19.7%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$1.77 Trailing P/E Ratio20.68 Forward P/E Ratio8.36 P/E Growth1.59Net Income$47.06 million Net Margins4.00% Pretax Margin5.97% Return on Equity13.84% Return on Assets6.05% Debt Debt-to-Equity Ratio0.85 Current Ratio2.29 Quick Ratio1.04 Sales & Book Value Annual Sales$1.37 billion Price / Sales0.80 Cash Flow$7.42 per share Price / Cash Flow4.93 Book Value$33.36 per share Price / Book1.10Miscellaneous Outstanding Shares30,110,000Free Float30,025,000Market Cap$1.10 billion OptionableOptionable Beta0.94 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:CNMD) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CONMED Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CONMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
